Study of Nasal Insulin to Fight Forgetfulness - Device Study

• Status: Active, not recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The SNIFF Device study will involve using a device to administer insulin through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using a nebulizer-like device on memory, blood, and cerebral spinal fluid.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Suzanne Craft; Wake Forest University Health Sciences
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Isophane

Criteria

Inclusion Criteria:

• Fluent in English

• Cognitively normal or diagnosis of aMCI

• Stable medical condition for 3 months prior to screening visit

• Stable medications for 4 weeks prior to the screening and study visits

• Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the study physician

Exclusion Criteria:

• A diagnosis of dementia

• History of a clinically significant stroke

• Current evidence or history in past two years of epilepsy, head injury with loss of consciousness, any major psychiatric disorder including psychosis, major depression, bipolar disorder

• Diabetes (type I or type II) insulin dependent and non-insulin dependent diabetes mellitus

• Current or past use of insulin or any other anti-diabetic medication within 5 years of Screening visit.

• History of cancer five years prior to screening (history of skin melanoma or stable prostate cancer are not exclusionary)

• History of seizure within past five years

• Pregnancy or possible pregnancy.

• Use of anticoagulants warfarin (Coumadin) and dabigatran (Pradaxa)

• Residence in a skilled nursing facility at screening

• Use of an investigational agent within two months of screening visit

• Regular use of alcohol, narcotics, anticonvulsants, antiparkinsonian medications, or any other exclusionary medications